Adjuvant temozolomide

DRUG2 trials

Sponsors

Oslo University Hospital, University of Michigan Rogel Cancer Center

Conditions

Glioblastoma

Phase 2

Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy

RecruitingNCT03548571

Oslo University HospitalGlioblastoma

Start: 2018-04-26End: 2026-05-01Target: 60Updated: 2024-04-03

Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

Active, not recruitingNCT04574856

University of Michigan Rogel Cancer CenterGlioblastoma

Start: 2020-11-04End: 2027-11-19Updated: 2026-03-25

Related Papers

A Phase 2 Study of Multiparametric Magnetic Resonance Imaging-Guided High-Dose Response-Adaptive Radiation Therapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma: Results From an Interim Analysis.

2025-03-08

NIMG-21. INTERIM ANALYSIS OF A PHASE II STUDY OF MULTIPARAMETRIC MR-GUIDED HIGH-DOSE RESPONSE-ADAPTIVE RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2022-11-012 citations

NEIM-08 A PHASE II STUDY OF MULTIPARAMETRIC MR-GUIDED HIGH DOSE ADAPTIVE RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology Advances2022-08-01